Psych Investor

A Long, Strange Trip: How the G.O.P. Came to Embrace Psychedelic Drugs - The New York Times nytimes.com/2026/05/03/sci…

ICYMI: Entropy Neurodynamics (#ASX: $ENP) reports a 75% response rate in treatment-resistant IBS in Phase 2a TRP-8802 trial, with results presented at DDW 2026, supporting a gut-brain mechanism and advancing TRP-8803 development. Read more: cdn-api.markitdigital.com/apiman-gateway…

@Entropy_Neuro 👏👏

Entropy Neurodynamics (#ASX: $ENP) reports a 75% response rate in treatment-resistant IBS in Phase 2a TRP-8802 trial, with results presented at DDW 2026, supporting a gut-brain mechanism and advancing TRP-8803 development. Read more: cdn-api.markitdigital.com/apiman-gateway…

Tobacco is one of the toughest drugs to quit, but psilocybin shows promise for helping people kick the habit. In the latest study, a single dose combined with talk therapy allowed half of participants to give up smoking. bbc.com/future/article…

@Josh__Hardman DMT

If FDA could approve one drug tomorrow (for any indication), which would you choose?

CPCR Medical Director, Dr. Sandeep Nayak, addresses the current state of ibogaine research in an interview with @sciam: “I firmly believe it should be studied and may be a very useful treatment, but the science for ibogaine is in a far more preliminary state than that of, say, psilocybin.” scientificamerican.com/article/rfk-jr…

Psychedelic medicine is moving from the margins into serious medical research. Ibogaine shows intriguing early promise for addiction, PTSD, and traumatic brain injury, especially among veterans. @gbh wgbh.org/radio-podcasts…

Every 11 minutes, we lose an #American to suicide. For our #veterans, the crisis is even more acute (avg. 17 deaths/day). 🎗️ We need more than the status quo. @US_FDA-regulated #psychedelic therapies are showing breakthrough potential to bridge this gap. #SuicidePrevention

Spravato is opening the door to a new generation of experimental depression therapies. bloomberg.com/features/2026-…

This excellent @business article by @g0ingmad highlights the strong success of Spravato - well worth a read. As I mentioned previously in my blog x.com/C_Angermayer/s… Spravato is indeed paving the way for psychedelic therapies. However, it is too simplistic to generalize. I strongly believe that commercial viability will determine the winners. Efficacy alone is not enough. Delivery and duration drive scalability. In my view, @ataibeckley's two lead assets - BPL-003 (5-MeO-DMT) and VLS-01 (DMT) - fit perfectly within the ~2-hour Spravato treatment window, with patient-friendly intranasal or buccal delivery. Importantly, they also could have the potential to outperform on both efficacy and the number of required treatment sessions. $ATAI

Psilocybin made human cells live 50% longer. A new study has uncovered surprising anti-aging potential in psilocin—the active metabolite produced when the body breaks down psilocybin, the psychoactive compound found in magic mushrooms. In laboratory experiments, researchers exposed two human cell lines (skin fibroblasts and fetal lung fibroblasts) to a 100 μM concentration of psilocin. The results were striking: lung cells took 57% longer to reach replicative senescence (the point at which cells permanently stop dividing and accumulate damage), while skin fibroblasts extended their replicative lifespan by 51%. These findings suggest psilocin may slow fundamental cellular aging processes, possibly by lowering oxidative stress, enhancing DNA-repair pathways, supporting mitochondrial health, or dampening chronic inflammation—mechanisms that overlap with those targeted by leading experimental longevity drugs. The benefits extended beyond cell culture. In aged female mice (19 months old at the start, equivalent to approximately 60–65 human years), a single monthly dose of psilocybin dramatically improved outcomes. After 10 months of treatment, 80% of the psilocybin-treated animals remained alive, compared with only 50% of untreated controls. Treated mice also displayed markedly fewer visible signs of aging, including reduced fur loss and graying. This research marks the first direct demonstration that psilocybin/psilocin can influence biological aging itself, rather than solely producing psychological effects. The authors emphasize that the study used relatively conservative dosing and are now advocating for follow-up work with higher or more frequent administration, detailed assessments of immune, metabolic, and cognitive function, and investigations into whether the extended lifespan corresponds to genuine improvements in healthspan and quality of life. ["Psilocybin treatment extends cellular lifespan and improves survival of aged mice." npj Aging, 2025]

Psychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions. trib.al/U2BxRSb

May is Mental Health Awareness Month — a time to recognize the millions of people living with depression, anxiety and other mental health conditions. At Helus Pharma, our mission is to help minds heal. Through rigorous, patient-centered research and disciplined clinical development, we are working to advance novel serotonergic agonists with the goal of addressing significant unmet needs in mental health. This month, we stand with patients, families, veterans, clinicians, researchers and communities working to expand awareness, reduce stigma and advance responsible innovation in mental health care.

My op ed in today's @WashPost - "Trump’s executive order on psychedelics strikes a healthy balance: The president preserved the FDA's role, even as some want the agency's gatekeeping dismantled." washingtonpost.com/opinions/2026/…

@C_Angermayer @business Shots fired 😉

The only psychedelic theraphy I see that not only fits seamlessly into the 2-hour Spravato window, but may even improve on it - potentially offering greater efficacy with far fewer sessions- is $ATAI BPL-003 (5-MeO-DMT) I’m happy to take on the challenge of beating J&J across every metric once approved.

Spravato is opening the door to a new generation of experimental depression therapies. bloomberg.com/features/2026-…

What if end-of-life care addressed more than physical pain? A single psilocybin session may help patients step out of loops of anxiety and see their life in a wider frame. Watch full episode: youtu.be/DqSDCm5fUqk

@Mastacash Def the most upside in the psychs space.

$HELP it will take the stock to move higher on volume to get noticed, but it won’t move higher on volume until it gets noticed. Most market participants do ZERO DD, they wait until the volume indicators flash and then come running. Many times they miss the first 100% or more when it happens fast. I was saying this regarding $SLNH now it’s tripled off the lows and just now X is boasting about it. Jokers could have bought at 58c instead of $1.80. It lived in the shadows while they had a great business model. This is how I still feel about $HELP, at some point there is go to be a move. They have a superior drug to comp360, but $CMPS gets all the attentionhelp, $HELP is in the shadows because the stock has underperformed. We shall see…

The data is in: @US_FDA-regulated #psychedelic therapies are proving to be a game-changer for hard-to-treat conditions. Over 60 clinical trials highlight their efficacy and safety, showing low potential for dependence in structured environments. 🥼